You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: CytoInformatics LLC Topic: NIA
DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: EXSCIEN CORPORATION Topic: NIDDK
DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SignalRx Pharmaceuticals Inc. Topic: NCI
PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Nectome Inc. Topic: 101
Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care ApplicationsSBC: GENECAPTURE, INC. Topic: CBD15C001
The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust moleculaSTTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
SBC: iXpressGenes, Inc. Topic: 100
Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.SBC: Acumen Pharmaceuticals, Inc Topic: NIA
In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CoPlex Therapeutics, LLC Topic: NIA
ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CAPRICOR, INC. Topic: NHLBI
DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NICHD
ABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health